References

1. MacIsaac, R.J., et al., *Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.* Diabetes Ther, 2023. **14**(12): p. 1997-2014.
2. Anderson, S.L. and J.C. Marrs, *Tirzepatide for type 2 diabetes.* Drugs Context, 2023. **12**.
3. Coskun, T., et al., *LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.* Mol Metab, 2018. **18**: p. 3-14.
4. Rizvi, A.A. and M. Rizzo, *The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.* Diabetes Metab Syndr Obes, 2022. **15**: p. 1023-1030.
5. Davies, M.J., et al., *Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).* Diabetes Care, 2022. **45**(11): p. 2753-2786.
6. Eli Lilly Australia Pty Ltd. *AUSTRALIAN PRODUCT INFORMATION – MOUNJARO® (TIRZEPATIDE) SOLUTION FOR INJECTION*. 2023 [cited 2023 18 October]; Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2023-PI-02114-1&d=20231018172310101.